The Fungal Threat to Public Health

A special issue of Journal of Fungi (ISSN 2309-608X). This special issue belongs to the section "Fungal Pathogenesis and Disease Control".

Deadline for manuscript submissions: closed (30 December 2022) | Viewed by 2344

Special Issue Editor


E-Mail Website
Guest Editor
Medical Mycology Reference Laboratory (MMRL), Institute of Microbiology and Immunology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
Interests: medical mycology; laboratory diagnosis; epidemiology; public health
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Fungal infections affect populations all over the world. Evidence of fungal biodiversity, antifungal resistance patterns, prevention and prediction concepts and different treatment approaches are of great importance. Additionally, evidence of differences in reach and resource-limited settings is less clear and seems to be very important. The evidence for public health control is also lacking.

Studies in these populations with randomisation and control groups are welcome as well as publications that develop guidelines for standardised clinical and public health management of skin, nail and hair infections in outpatients, and hospital-based studies on high-risk patients of invasive fungal infections from different countries.

Prof. Dr. Valentina Arsić Arsenijević
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Fungi is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • fungal infections
  • dermatophytes
  • Candida
  • Aspergillus
  • invasive fungal infections
  • public health control
  • hospital control

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

11 pages, 663 KiB  
Article
Characteristics and Outcomes of Cryptococcosis among Patients with and without COVID-19
by Daniel B. Chastain, Vanessa M. Kung, Lilian Vargas Barahona, Brittany T. Jackson, Sahand Golpayegany, Carlos Franco-Paredes, George R. Thompson III and Andrés F. Henao-Martínez
J. Fungi 2022, 8(11), 1234; https://doi.org/10.3390/jof8111234 - 21 Nov 2022
Cited by 3 | Viewed by 1924
Abstract
The effect of COVID-19 on the risk and prognosis of cryptococcosis is unclear. We compared the characteristics and outcomes of cryptococcosis in patients with and without COVID-19. Patients 18 years and older with cryptococcosis were identified from TriNetX and separated into two cohorts [...] Read more.
The effect of COVID-19 on the risk and prognosis of cryptococcosis is unclear. We compared the characteristics and outcomes of cryptococcosis in patients with and without COVID-19. Patients 18 years and older with cryptococcosis were identified from TriNetX and separated into two cohorts based on a diagnosis of COVID-19 within 3 months of the index diagnosis of cryptococcosis. Differences examined between groups included comorbidities, immunosuppressive medications, ED visits, hospitalizations, ICU admissions, mechanical ventilation, and deaths. The propensity score matching was performed based on demographics and comorbidities. Of the 6998 patients with cryptococcosis included, 4.4% (n = 306) had COVID-19 prior to cryptococcosis. Mortality was higher in patients with COVID-19 compared to those without COVID-19 (14% vs. 11%, p = 0.032). Additionally, those with COVID-19 were older (55.2 ± 14.4 vs. 51.9 ± 15.2 years, p < 0.001) with higher rates of transplant (29% vs. 13%, p < 0.001), neoplastic disease (37% vs. 21%, p < 0.001), chronic kidney disease (42% vs. 18%, p < 0.001), or diabetes (35% vs. 19%, p < 0.001) but not HIV (30% vs. 31%, p = 0.618). Glucocorticoid use was more common in those with COVID-19 (52% vs. 27%, p < 0.001). More patients with COVID-19 required ED visits (29% vs. 23%, p = 0.025) and ICU admission (18% vs. 11%, p < 0.001). After propensity score matching, patients with COVID-19 had higher rates of neoplastic disease, heart failure, chronic kidney disease, and glucocorticoid use but did not experience worse outcomes compared to those without COVID-19. Patients with COVID-19 who developed cryptococcosis had independently higher rates of comorbidities and glucocorticoid use but similar outcomes, including death, versus those without COVID-19. Full article
(This article belongs to the Special Issue The Fungal Threat to Public Health)
Show Figures

Graphical abstract

Back to TopTop